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Abstract  
Objectives  To evaluate the evidence for the clinical effectiveness of neonatal screening for 
phenylketonuria (PKU) and medium-chain acyl-coA dehydrogenase (MCAD) deficiency using 
tandem mass spectrometry (tandem MS). 
Study design  Systematic review of published research 
Data sources  Studies were identified by searching 12 electronic bibliographic databases; 
conference proceedings and experts consulted. 
Results  Six studies were selected for inclusion in the review.  The evidence of neonatal 
screening for PKU and MCAD deficiency using tandem MS was primarily from observational 
data of large-scale prospective newborn screening programmes and systematic screening studies 
from Australia, Germany and the USA.  Tandem MS based newborn screening of dried blood 
spots for PKU and/or MCAD deficiency was shown to be highly sensitive (>93.220%) and 
highly specific (>99.971%).  The false positive rate for PKU screening was less than 0.046% and 
for MCAD deficiency the false positive rate was less than 0.023%. The positive predictive 
values ranged from 20 to 32% and 19 to 100%, respectively. 
Conclusions  This review suggests that neonatal screening of dried blood spots using a single 
analytical technique (tandem MS) is highly sensitive and specific for detecting cases of PKU and 
MCAD deficiency, and provides a basis for modelling of the clinical benefits and potential cost-
effectiveness. 
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Introduction  
Inborn errors of metabolism (IEM) are a rare group of genetic disorders that can have serious 
clinical consequences for an affected neonate or young infant.  If undiagnosed and untreated, 
these disorders can cause irreversible mental retardation, physical disability, neurological 
damage and even fatality.1  Detection and accurate diagnosis soon after birth are important for 
achieving a rapid and favourable patient outcome.  Whilst the incidence of each specific 
metabolic disorder is rare, their collective importance is deemed to be of considerable public 
health significance.2  The most common disorders of IEM are phenylketonuria (PKU) and 
medium chain acyl-coA dehydrogenase (MCAD) deficiency.2;3  In the UK, PKU and congenital 
hypothyroidism are the only disorders screened for routinely.  Evidence indicates that the 
screening programme is very effective with few cases having been missed.4  The UK screening 
programme for PKU is based on the application of three standard methods: the Guthrie bacterial 
inhibition assay, fluorometry, and chromatography.  Neonatal screening for MCAD deficiency 
has not yet been introduced in the UK, primarily because this disorder is not detectable with 
current screening methods.5  There has also been uncertainty about the natural history of MCAD 
deficiency and concerns about the specificity of the screening test.6 
  
Tandem mass spectrometry (tandem MS) has the capability to detect a much wider range of 
metabolic disorders than conventional methods.2;3;7  Analysis for these additional conditions can 
be undertaken using the same blood spot sample provided for PKU: no additional specimen 
collection or sample preparation is required.  Analysis of samples by tandem MS is rapid, can be 
performed in large batches and, with automatic sample introduction, processed in 24 hours.8  
This technology has been demonstrated to be suitable for the reliable detection of PKU9 and 
some other IEM’s.10-12  Of the many metabolic disorders that can be detected, MCAD deficiency 
is the most comprehensively studied.13 
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In 1997, two reports were published2;3 by the UK NHS R&D Health Technology Assessment 
(HTA) Programme, examining the case for extending the neonatal screening programme.  These 
reports were generally favourable to the introduction of some screening for selected disorders but 
with caveats.  They placed a high priority on evaluating MCAD deficiency and recommended 
further studies on the application of tandem MS to neonatal screening.  The failure to fund these 
studies left many stakeholders disappointed and frustrated.14;15  However, with the subsequent 
widespread, international development and adoption of newborn-screening programmes using 
tandem MS,16  the HTA Diagnostic Technologies & Screening Panel commissioned an updated 
review with economic modelling.  We conducted a systematic review of the evidence to assess 
the clinical effectiveness of neonatal screening for IEM’s using tandem MS.17  This paper 
summarises and updates the key findings of the HTA review17 in respect of PKU and MCAD 
deficiency only. 
 
Methods 
Twelve electronic bibliographic databases were searched in June 2003 (including the Cochrane 
Library, Medline, EMBASE and CINAHL) covering the biomedical, scientific, and grey 
literature.17 The search combined free text and thesaurus terms relating to neonatal screening for 
IEM using tandem MS.  No date or publication type restrictions were applied.  The full search  
strategy is available from the authors.  Searches were supplemented by hand searching relevant 
journals and conference proceedings. 
 
Diagnostic study types that provided data on the sensitivity, specificity or positive predictive 
value of neonatal screening using tandem MS for PKU and/or MCAD deficiency between June 
1996 (the date of the previous systematic literature search)2;3 and June 2003 were included in the 
review.  No language restrictions were applied to searches, though only, English language papers 
were considered for inclusion.  
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Selected papers were read and critically appraised by a single reviewer. Relevant information 
from included studies was abstracted directly into an evidence table.  Uncertainties were 
resolved by discussion with another reviewer and clinical advisers.  The quality of evidence for 
diagnostic and screening studies was assessed using established guidelines.18;19  20Summary 
results were tabulated with detailed descriptive qualitative analyses and were considered for 
quantitative meta-analysis. 
 
Results 
We identified 68 potential studies, published after June 1996 (data prior to this date incorporated 
in included studies), on neonatal screening for IEM using tandem MS, of which six were 
included in the review (Figure 1).  Table 1 lists study characteristics. 
 
Six studies assessed newborn screening for PKU and/or MCAD deficiency using tandem MS.  
These studies provided data from newborn screening programmes in Australia21 and the USA22;23 
and from systematic screening studies (non-newborn screening programmes) from the UK,6 
Germany25 and the USA.24  Five used a prospective cohort design with study durations from 
approximately two21;23 to seven24 years.  The UK study, of approximately three years, used a 
retrospective cohort design.6  All newborn dried blood spot specimens from Australia,21 
Germany25 and the USA22-24 were obtained within seven days after birth.23;24;26  The UK study 
did not report the timings, though standard UK practice is between six and 14 days of age.  
Diagnosis of PKU or non-PKU hyperphenylalaninaemia was generally established using repeat 
analysis and/or repeat blood spot specimens.23;25  Various thresholds were used to identify 
infants with MCAD deficiency (Table 1).   
 
 6 
Table 2 summarises the diagnostic sensitivity, specificity and positive predictive value of 
tandem MS.  Quantitative meta-analysis was not undertaken because of clinical heterogeneity of 
the studies. 
 
The false positive rate of PKU screening was less than 0.046%.23;25  In one program,23 92 infants 
were flagged for phenylalanine.  Of these, seven were identified with PKU and 11 with non-
PKU-hyperphenylalaninaemia (i.e. the positive predictive value of 19.565%).  If the 
phenylalanine concentration and the phenylalanine to tyrosine ratio were both considered, then 
the positive predictive value increased to 28.125%.  In a systematic screening study of 250,000 
newborns,25 the sensitivity for PKU screening was 93.220%.  However, if the milder form of the 
disease (non-PKU-hyperphenylalaninaemia) was excluded, the diagnostic sensitivity increased to 
100%.   
 
Results obtained from prospective newborn screening programmes for MCAD deficiency 
showed that the false positive rate was less than 0.023%,21-23 whereas in systematic screening 
studies the false positive rate was less than 0.018%.6;24;25  In one study 21 eleven infants were 
identified as false positives, although, four died before a second sample could be collected.  
MCAD deficiency was eliminated by enzyme analysis in cultured skin fibroblasts in one patient, 
whereas MCAD deficiency in the other three infants was eliminated on the basis of information 
obtained from clinicians and post-mortem findings. 
  
Only one programme reported the presence or absence of false negative results: no known false 
negative results were found.22  None of the prospective studies included a rigorous method to 
identify those who might have been missed by the screening process.  The UK retrospective 
study6 did not identify any false negative results after examination of the regional registers for 
metabolic diseases and deaths.  In this study,6 the sensitivity of the screening process was also 
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found to be 100%, however, the authors reported that the sensitivity of the test was difficult to 
ascertain, because many occurrences of MCAD deficiency were not diagnosed on clinical 
grounds.   
 
Discussion 
A systematic review of the published literature shows that neonatal screening of dried blood 
spots for PKU and MCAD deficiency is highly sensitive and highly specific using a single 
analytical technique (tandem MS).   
 
The evidence of neonatal screening for PKU and MCAD deficiency using tandem MS is 
primarily from observational data of large-scale prospective newborn screening programmes and 
systematic screening studies.21-25  Randomised controlled trials of screening for rare disorders are 
difficult because of the enormous numbers that would be needed for adequate power.21  
Observational data from large-scale prospective collaborative studies can provide information on 
test and programme performance and clinical outcome to guide policy decisions.3;14;27 
 
Despite the high sensitivities6;22;25 and high specificities6;21-25 of tandem MS based neonatal 
screening for both PKU and MCAD deficiency, the diversity in the preferences of metabolites 
together with the cut-off limits used to define a positive outcome restricts direct comparison of 
the diagnostic performance between studies.   
 
The positive predictive value for identification of PKU and MCAD deficiency was found to be 
higher than that for the disorders screened by the traditional, non tandem MS methods (0.5 to 
6.0%).28  Compared with previously used diagnostic methods (bacterial inhibition assay, 
fluorometric assay), tandem MS based screening can be performed earlier with lower false 
positive rates.7;9;29;30  Detection of milder variants of a disorder can be addressed by adjusting the 
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cut-off levels closer to normal limits.31-33  Octanoylcarnitine is the predominant marker for 
MCAD deficiency, however it is not specific for MCAD deficiency and is expected to be 
elevated for other disorders and in neonates treated with valproate or fed a diet high in medium-
chain triglycerides.34  Most of the included studies used different criteria’s to confirm a 
diagnosis.  In two studies from the USA,22;24 infants were considered to have MCAD deficiency 
solely on the basis of diagnostic acylcarnitine profiles whereas Carpenter et al.,21 Schulze et al.25 
and Zytkovicz et al23 applied explicit criteria for the diagnosis of MCAD deficiency.  In the UK 
retrospective study,6 which used explicit criteria for diagnosis of MCAD deficiency, the authors 
reported that in most cases of MCAD deficiency, diagnosis was not based on clinical grounds 
but developed symptoms in early childhood.  
 
Worldwide, there is an increasing trend to discharge mother and baby within the first day or two 
of life.26  In this review, most dried blood spot samples obtained in prospective newborn 
screening studies were collected less than 72 hours after birth,22-24;26 which is considerably 
earlier than in the UK, where neonatal screening samples are normally collected between six and 
14 days of life.2;3  The age at which screening is undertaken will affect the sensitivity and 
specificity of the screening process as concentrations of metabolites change over time.  For 
example, in the UK, specimen collection is delayed until the sixth day of life or later in order to 
maximise sensitivity for the PKU screen.3  The earlier collection of newborn blood spots in the 
UK might facilitate quicker and more clinically effective therapy.  However, it might also 
influence test performance, underlining the need for a better infrastructure to support clinical 
follow-up, management and high quality clinical services for identified cases and their 
families.2;14  Clayton and co-workers,12 who reported their experience in diagnosing MCAD 
deficiency in a UK population concluded that if neonatal screening were undertaken at seven to 
ten days, the number of false positive and false negative results should be negligible. 
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The UK newborn screening programme for PKU is well established and there is universal 
agreement that neonatal screening for PKU is justified.2;3;35;36  The mainstay of treatment for 
MCAD deficiency is a high carbohydrate intake, orally or intravenously during fasting and/or 
intercurrent illness.37  The key concern regarding screening for this disorder is that the 
presentation varies widely with some individuals not presenting until they are adults, and an 
unknown number remaining undiagnosed or asymptomatic.14  Potential consequences of 
diagnosis for this group include anxiety about the risk of hypoglycaemia during early childhood 
and adverse effects of clinically unwarranted treatment.27  However, it has been suggested that 
such individuals are at as much risk as the symptomatic cases but are fortunate not to have 
encountered a sufficient metabolic stress to trigger a crisis.  As a result, all babies with MCAD 
deficiency detected by newborn screening are at risk and treatment is required in all. 38 
 
Tandem MS equipment is now in use in at least five major centres in the UK, resulting in a 
centralised ‘core’ of knowledge and experience in this country.8  This review suggests that 
tandem MS is highly sensitive and specific for detecting PKU and MCAD deficiency.   The 
evidence base provides a basis for a review of clinical benefit and the economic attractiveness of 
using tandem MS for PKU and MCAD deficiency screening. 
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Figure 1.  Study flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant papers identified and screened for 
retrieval (up to June 2003) (n=202) 
Papers retrieved for more detailed evaluation (n=68) 
Potentially appropriate papers to be included in systematic 
review (n=16) 
Studies with usable information on PKU and MCAD 
deficiency (n=6) 
 
Data on PKU only (n=0) 
Data on MCAD deficiency only (n=4) 
Data on PKU and MCAD deficiency (n=2) 
Studies excluded if not neonatal screening 
using tandem MS. Studies included in 
earlier reviews also excluded i.e. prior to 
June 1996 (n=134) 
Studies excluded: No data on the 
sensitivity, specificity or positive 
predictive value of neonatal screening 
using tandem MS (n=52) 
Studies without data on PKU and/or 
MCAD deficiency were excluded (n=10) 
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Table 1.  Study and population characteristics 
 
Study Study type Location Population Sample type and 
Age at sampling 
Target 
condition(s) 
Threshold for disease 
identification 
Confirmatory test 
Newborn screening programmes       
Carpenter et al. 200121 Prospective 
cohort study 
New South 
Wales Newborn 
Screening 
Programme, 
Australia 
  
Consecutive neonates 
undergoing routine 
newborn screening 
(>99%) in New South 
Wales and Australian 
Capital Territory 
between April 1998 and 
March 2001.  Ethnicity 
not reported 
Analysis of 
acylcarnitines as 
their butyl esters 
from dried blood 
spot samples taken 
at 3 days (median).  
Over 99% of babies 
were sampled 
before day 6 
 
MCAD 
deficiency 
Octanoylcarnitine 
concentration ≥1 μmol/L  
 
Polymerase chain reaction assay for 
985A®G mutation, analysis of 
plasma, repeat blood spot 
acylcarnitines and urinary organic 
acids and fibroblast fatty acid 
oxidation 
 
Patients were diagnosed with MCAD 
deficiency if one or more of the 
following criteria were met: 
homozygous for 985A®G mutation, 
raised hexanoylglycine and 
suberylglycine in urine, increased 
hexanoylcarnitine, octanoylcarnitine 
or decenoylcarnitine in plasma; 
studies of fibroblast fatty acid 
oxidation rate or acylcarnitine studies 
Chace et al. 199722 Prospective 
cohort study 
Pennsylvania & 
North Carolina 
Newborn 
Screening 
Program, USA 
Newborn infants 
screened between 
September 1992 and 
January 1997. Ethnicity 
not reported 
Analysis of 
acylcarnitines as 
their butyl esters 
from dried blood 
spot samples taken 
<72 hours after 
birth 
MCAD 
deficiency 
Octanoylcarnitine 
concentration ≥0.3 µmol/L 
DNA analysis for 985A®G mutation 
and repeat blood spot analysis of 
octanoylcarnitine 
Zytkovicz et al. 200123 Prospective 
cohort study 
New England 
Newborn 
Screening 
Program, USA 
 
Newborn infants 
screened over a two-year 
period from February 
1999.  Ethnicity not 
reported 
 
Analysis of 
acylcarnitines and 
amino acids as their 
butyl esters from 
dried blood spot 
samples taken 
between 1 and 3 
days after birth 
PKU and MCAD 
deficiency 
 
PKU 
Phenylalanine concentration 
>139 µmol/L; phenylalanine to 
tyrosine ratio >1.5 
 
MCAD deficiency 
Octanoylcarnitine 
concentration >0.5 µmol/L 
Re-tested original samples and 
confirmation of disorders according to 
standard metabolic procedures.  For 
MCAD deficiency, DNA analysis for 
985A®G mutation and raised 
hexanoylglycine and suberylglycine 
in urine 
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Table 1.  Study and population characteristics-continued from previous page 
 
Study Study type Location Participants Sample type and 
Age at sampling 
Target 
condition(s) 
Threshold for disease 
identification 
Confirmation test 
Systematic screening studies (non-newborn screening programmes)     
Andresen et al. 200124 Prospective 
cohort study 
Pennsylvania, 
Ohio, New 
Jersey, Illinois, 
Florida, North 
Carolina, USA 
Newborn infants born 
between December 1992 
and January 2001. 
Ethnicity not reported 
Analysis of 
butylated 
acylcarnitines from 
dried blood spot 
samples taken <72 
hours after birth 
MCAD 
deficiency 
Mild profile defined as 
octanoylcarnitine 
concentration of 0.5 to 2.0 
µmol/L with octanoylcarnitine 
to decanoylcarnitine ratio of 2 
to 4; Severe profile defined as 
octanoylcarnitine 
concentration >2 µmol/L and 
octanoylcarnitine to 
decanoylcarnitine ratio of >4 
Repeat analysis, repeat blood spot 
specimen (if possible) and mutations 
verified by DNA assay 
Pourfarzam et al. 20016 Retrospective 
cohort study 
Northern region 
of the National 
Health Service, 
UK 
Newborn infants born 
between January 1991 
and July 1993.  Ethnicity 
not reported 
Analysis of 
butylated 
acylcarnitines from 
stored (4˚C for up 
to 4 years) dried 
blood spot samples.  
Age of sampling 
not reported 
MCAD 
deficiency 
Octanoylcarnitine 
concentration >0.3 µmol/L 
with octanoylcarnitine to 
hexanoylcarnitine ratio >4.0 
Analysis of acylcarnitine in blood, 
organic acids in urine (suberylglycine, 
phenylpropionyl-glycine, and 
hexanoylglycine), free and total 
carnitine in plasma, molecular genetic 
test (DNA analysis for 985A®G 
mutation) and fibroblast fatty 
oxidation 
Schulze et al. 200325 Prospective 
cohort study 
Baden-
Wűrttemberg, 
Germany 
Newborn infants born 
between April 1998 and 
September 2001.   
>98% white 
Analysis of 
acylcarnitines and 
amino acids as their 
butyl esters from 
dried blood spot 
samples taken 
between 3 to 7 days 
(median 5 days) 
PKU and MCAD 
deficiency 
 
PKU 
Phenylalanine concentration 
>150 µmol/L; phenylalanine to 
tyrosine ratio >1.7 
 
MCAD deficiency 
Hexanoylcarnitine 
concentration >0.21 µmol/L 
and /or octanoylcarnitine >0.32 
µmol/L; decenoylcarnitine 
>0.28 µmol/L; 
decanoylcarnitine >0.48 
µmol/L or molar ratio 
octanoylcarnitine to 
acetylcarnitine >0.02; 
octanoylcarnitine to 
decanoylcarnitine >1.6; 
octanoylcarnitine to 
dodecanoylcarnitine >1.6 
PKU: phenylalanine >600 μM; non-
PKU-hyperphenylalaninaemia, 
phenylalanine >150 and <600 μM. 
 
 
MCAD deficiency: enzyme activity in 
fibroblasts/ lymphocytes; mutational 
analysis; phenyl propionate loading; 
hexanoyl and suberylglycine in urine 
and enzyme residual activities. 
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Table 2.  Effectiveness of neonatal screening for phenylketonuria and medium-chain acyl-CoA dehydrogenase deficiency using tandem MS 
 
Disorder Author Total 
screened 
True 
Positives 
False positive 
(Specificity %) 
False negatives 
(Sensitivity %) 
Positive 
predictive 
value (%) 
       
PKU Schulze et al. 200325 250,000 55* 115 (99.954) 4 (93.220)‡ 32.353 
       
 Zytkovicz et al. 200123 257,000 18† 
 
74 (99.971) Not reported 19.565 
       
       
MCAD Carpenter et al. 200121 275,653 12 11 (99.996) Not reported 52.174 
 Chace et al. 199722 283,803 16 0 (100.000) 0 (100.000) 100.000 
 Zytkovicz et al. 200123 184,000 10 42 (99.977) Not reported 19.231 
       
 Andresen et al. 200124 930,078 62 0 (100.000) Not reported 100.000 
 Pourfarzam et al. 20016 100,600 8 0 (100.000) 0 (100.000) 100.000 
 Schulze et al. 200325 250,000 16 46 (99.982) 0 (100.000) 25.806 
       
PKU, phenylketonuria; MCAD, medium-chain acyl-CoA dehydrogenase deficiency; HPA, hyperphenylalaninaemia 
* 24 Classic PKU, 31 non-PKU-hyperphenylalaninaemia 
† 7 Classic PKU, 11 non-PKU-hyperphenylalaninaemia 
‡ All 4 false negative cases were non-PKU-hyperphenylalaninaemia 
 
 
 
